Resveratrol (RSV) is reported to extend life span 1,2 and provide cardio-neuro-protective 3 , antidiabetic 4 , and anti-cancer effects 3,5 by initiating a stress response 2 that induces survival genes. Because human tyrosyl tRNA synthetase (TyrRS) translocates to the nucleus under stress conditions 6 , we considered the possibility that the tyrosine-like phenolic ring of RSV might fit into the active site pocket to effect a nuclear role. Here we present a 2.1Å co-crystal structure of RSV bound to the active site of TyrRS. RSV nullified the catalytic activity and redirected TyrRS to a nuclear function, stimulating NAD + -dependent auto-poly-ADP-ribosylation of PARP-1. Downstream activation of key stress signaling pathways were causally connected to TyrRS-PARP-1-NAD + collaboration. This collaboration was also demonstrated in the mouse, and was specifically blocked in vivo by a RSV-displacing tyrosyl adenylate analog. In contrast to functionally diverse tRNA synthetase catalytic nulls created by alternative splicing events that ablate active sites 7 , here a non-spliced TyrRS catalytic null reveals a new PARP-1-and NAD + -dependent dimension to the physiological mechanism of RSV.
Cell lysates treated with the PARG hydrolyase and its hydrolase-inactive mutant supported that TyrRS preferentially bound to non-PARylated PARP-1 (Extended Data Fig. 3d,e) . TyrRS interacted specifically with the C-domain of PARP-1 (CT-PARP-1) (Extended Data Fig. 3f ). Neither mini-TyrRS nor the TyrRS C-domain interacted with PARP-1; only fulllength native TyrRS bound PARP-1 (Extended Data Fig. 3g,h ). In the absence of RSV, concentration-dependent activation of PARP-1 by TyrRS was observed in vitro (Fig. 2a , top, Extended Data Fig. 4a,b) . RSV enhanced in-vitro auto-PARylation with the half-maximal effect at roughly 10 nM (Fig. 2a, middle) , well below the Ki (about 22 μM) in Extended Data Figure 1a -c. Thus, PARP-1 may alter the apparent affinity of RSV for TyrRS. Also, concentration-dependent quenching of PARylation of PARP-1 by Tyr-SA was evident (Fig.  2a, bottom) . Lastly, while broken DNA normally activates PARP-1 13 , Tyr-SA did not interfere with this DNA-dependent-pathway of PARP-1 activation in vitro (Extended Data  Fig. 4c ). Therefore, TyrRS-RSV activation of PARP-1 is distinct.
Ectopically expressed TyrRS in HeLa cells for 0-24 h caused progressive increase in cellular concentrations of the synthetase (Fig. 2b, top) and a correlated progressive increase in PARP-1 PAR (Fig. 2b, top) . A TyrRS mutant (TyrRS-dNLS), with reduced nuclear localization 6 , reduced activation of PARP-1 (Extended Data Fig. 4d ). Effects of RSV exvivo at various concentrations (Fig. 2b, middle) and of Tyr-SA (Fig. 2b , bottom) mirrored those seen in vitro (Fig. 2a , middle and bottom).
RSV and L-tyrosine produce different bound conformations of TyrRS, seen locally in the high-resolution structures of the two co-crystals ( Fig. 1b and Extended Data Fig. 2a ). These differences could affect the disposition of the C-domain needed for the interaction of TyrRS with PARP-1. This domain is tethered to the mini-TyrRS catalytic unit by a flexible linker (Fig. 2c, left) . By breaking the Y341 OH--H-bond to a backbone carbonyl oxygen, a Y341A mutation releases tight tethering of the C-domain to the catalytic domain 15 and its reorientation 16 (Fig. 2c, right) .
In the absence of RSV, Y341A-TyrRS showed robust interaction with and activation of PARP-1 in vitro (Fig. 2d) . If Y341A is shifted more towards a conformation needed to bind to PARP-1, then it would be more sensitive than WT TyrRS to low concentrations of RSV. This expectation was fulfilled (Extended Data Fig. 4e ). TyrRS-Tyr may thus have a conformation that prevents interaction with PARP-1, while TyrRS-RSV has a distinct conformation that binds PARP-1. In the absence of either ligand, a dynamic equilibrium populates both forms (Fig. 2c) .
A working model of downstream signaling markers was developed as detailed in Methods (Fig. 3a) . Effects from serum starvation and RSV administration involve cascades through protein acetylation and phosphorylation effects of serum starvation and of RSV, which have not been linked to TyrRS nor activation of PARP-1. Under conditions of serum starvation or RSV administration, the response in HeLa cells of PARylated and acetylated proteins, together with the aforementioned cell-signaling proteins, was monitored for up to 1h. Either RSV or serum-starvation promoted production of AcK-Tip60 and AcK-ATM (Fig. 3b) . In a temporal response from 0 to 8 h, either or both of serum starvation or 1 μM RSV promoted increased levels of whole cell acetylated proteins, Hsp72, AcK382-p53, p-AMPK, pSer36-H2B, p21, FOXO3A, 14-3-3, HO-1, NAMPT, SIRT1 and SIRT6 (Fig. 3c,d ). Also, RSV activated acetylation of Tip60 ex-vivo in a concentration-dependent manner (Extended Data  Fig. 5a ). As expected from previous reports that acetylation of p53 is indispensible for its activation 17 , a transient increase in acetylation of p53 (AcK382) 1 was evident (Fig. 3c,d ), possibly through a transient inhibition of SIRT1 by the nicotinamide 18 being produced. Consistently, at 15 min, a RSV concentration-dependent reduction in total NAD + with concomitant production of nicotinamide and ADP-ribose was observed (Extended Data Fig.  5b,c) . Thus, serum starvation and RSV rapidly increased all monitored proteins in a way that is dependent on having active PARylation. This rapid increase is consistent with work showing rapid upregulation of PARP-1 target genes 19, 20 , possibly due to a broader effect of PARP-1 on transcription and associated stress signaling 13, 21 .
At longer times, and continuing at low concentrations (≤ 10 μM) of RSV, similarity between responses to RSV and serum starvation was ostensibly seen. By 1h, low concentrations of RSV elevated the NAD + levels similar to those of serum-starvation conditions (Extended Data Fig. 5d ). Responses of key stress-signaling markers in a more extended period of 8-24 hours at 5 μM RSV were mostly similar to those of serum starvation (Extended Data Fig.  5e ,f). At 5 μM RSV, levels of PARP-1 PAR were sustained longer when compared with what was observed at 1 μM RSV (compare 2, 8 h time points in Figure 3d with Extended Data Fig. 5f ) and we thus continued further studies at 5 μM RSV. An si-RNA directed against PARP-1 (siRNA PARP-1 ) effectively abrogated the RSVstimulated expression of Hsp72, p-AMPK, SIRT1, FOXO3A, SESN2, NAMPT, PUMA and SIRT6 (Fig. 4a) . Also, 5 μM RSV promoted induction of BRAC1 and p14ARF (whose genes are directly regulated by PARP-1 22, 23 ). Consistently, the RSV-stimulated induction of BRCA1 and p14ARF were prevented by siRNA PARP-1 (Fig. 4a) , further showing involvement of PARP-1 in RSV-mediated induction of these proteins.
In figure 4a , RSV treatment led to enhanced activation of p53. However, in the absence of RSV, knockdown of PARP-1 resulted in a background increase in the products of these p53-regulated genes. Possibly p53 was activated by the knockdown of PARP-1, because removal of PARP-1 would enhance background levels of DNA damage. Indeed, activation of p53, as seen by enhanced acetylation and phosphorylation of p53, was observed (Fig. 4a) .
siRNA TyrRS -knockdown at 5 μM RSV eliminated induction of, and dramatically reduced amounts of, PARylated PARP-1, of whole acetylated proteins, and of AcK382-p53, AcK16-H4 (Tip60 activation), p-AMPK, and pSer36-H2B (AMPK activation) ( Although the RSV-TyrRS-PARP-1 axis initially consumes NAD + , at low RSV (5 μM), NAD + levels are transiently raised after 1 h due to NAMPT activation (Extended Data Fig.  5d ). At 1 h at low RSV, induction of NAD + levels was abolished with either siRNA TyrRS or siRNA PARP-1 (Extended Data Fig. 8 ). NAD + depletion by NAMPT inhibition abolished RSV-mediated induction of BRCA1, FOXO3A, NAMPT, SESN2 and SIRT6 (Fig. 4c) . These results are consistent with those using inhibitors against PLC-γ and the ryanodine receptor 25 , which inhibit PARP-1 activation 26 and ADP-ribose-mediated calcium signaling 25, 27 , and which prevented RSV-mediated AMPK activation. Similarly, a PARP-1 inhibitor prevented LKB1 activation by RSV 28 .
Mice were injected through tail vein-IV with 100 μl of 10 μM RSV and, after 30 min, were sacrificed. Compared to the PBS IV-injected control, PARylated and acetylated proteins, along with AcK16-H4 and pSer36-H2B, were significantly increased in skeletal muscle (Extended Data Fig. 9a,b) . Results in cardiac tissue were similar (Extended Data Fig. 9c,d ).
In addition, PARP-1 activation diminished back to normal by 24 h (Extended Data Fig. 9e ). Consistent with ex-vivo assays, tissue samples from RSV-injected mice showed higher levels of TyrRS-PARP-1 interaction together with increased auto-PARylation (Extended Data Fig. 9f ).
Tyr-SA (5 μM) was added to the IV-injection with RSV. No interaction of TyrRS with PARP-1 could be detected in skeletal or cardiac muscle and levels of PARylated and acetylated proteins did not increase. In contrast, co-injection of Gly-SA or cycloheximide (CHX, protein synthesis inhibitor) did not block RSV/TyrRS-mediated activation of PARP-1 and its downstream signals ( Fig. 4d (muscle) , Extended Data Fig. 9g ,h (cardiac)). Consistent with ex-vivo assays, immuno-precipitation of PARP-1 (from harvested muscle tissue) pulled-down TyrRS, and immuno-precipitation of p53 showed its increased acetylation. Pulldown of TyrRS and p53 acetylation were blocked in mice that had coinjections of Tyr-SA or the AG14361 (SelleckChem) PARP-1 inhibitor, but not of Gly-SA or cycloheximide (Fig. 4e ). These responses in vivo parallel ex-vivo assays, and support that TyrRS is a major effector target for RSV that acts through PARP-1 as described in figure 3a.
The mechanism of action of RSV and of the stress response are both linked here to the activation of PARP-1 through TyrRS and NAD + . The interaction of RSV with TyrRS could be viewed as an example of xenohormesis through interactions of a natural ligand with a protein target 29 . In this instance, the natural ligand blocks the active site to create a tRNA synthetase catalytic null with a new, orthogonal function. This kind of catalytic null is in contradistinction to those created by alternative splicing events that specifically remove the active site 7 . The RSV-TyrRS activation of PARP-1 is readily observable in a functional in vitro assay even at sub-micromolar concentrations (e.g., 10 -20 nM, Fig. 2a middle) . Thus, TyrRS-RSV-induced PARP-1 activation appears at significantly lower RSV concentrations than seen with RSV functional binding to other targets 1, 25, 30 . As a consequence, the direct effects of RSV binding to these targets of RSV are layered over a pre-existing foundation that comes from the TyrRS-RSV-PARP-1-NAD + connection.
METHODS

Construction of the working model as illustrated in figure 3a
Because both RSV and serum starvation activate PARP-1 leading to the metabolic breakdown of NAD + into nicotinamide and ADP-ribose, downstream signaling markers associated with the NAD + metabolic flux were investigated. Targets were selected if they were activated and/or inhibited under conditions of RSV-treatment, stress or NAD + metabolic byproduct-treatment (nicotinamide and ADP-ribose). For example, nicotinamide activates Tip60 31 through SIRT1 inhibition 18 and Tip60 activates ATM 32 , the p53 kinase. p53 is a master regulator of NRF2 through p21 induction 33 42 and hence an indispensible component for AMPK activation by resveratrol 43 and the stress response by phosphorylating H2B 44 . AMPK is known to upregulate NAMPT expression 45 , the major regulator of NAD + levels in the cell 46 . NAD + is major substrate for sirtuins (deacetylation or mono-ADP-ribosylation 38, 47, 48 ) and PARPs ((mono/poly)-ADPribosylation 13, 49 ). Although not depicted, p38 and NF-kB (major transducers of stress signaling) are also regulated by TAK1 in a PARP-1/ATM dependent manner 50, 51 .
Antibodies
All antibodies were obtained from Cell Signaling Technology (Danvers, MA) unless and otherwise mentioned. α-ATM was from Abcam (Cambridge, MA) and GeneTex (San Antonio, TX). α-PARP-1 and α-poly(ADP-ribose) were from BD Biosciences (Franklin Lakes, NJ). α-p84 was from Sigma (St. Louis, MO). α-pSer36-H2B from ECM Biosciences. Rabbit α-human TyrRS polyclonal antibodies were homemade. α-Tip60 was from Millipore (Billerica, MA). α-AcK16-H4 was from Active Motif (Carlsbad, CA) and α-Hsp72 (cat # SPA-812) was from assay designs (Ann Arbor, MI).
Cell culture, transfection and resveratrol treatment
HeLa cells (from ATCC, mycoplasma free) were cultured in a humidified incubator with 5% CO 2 in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Invitrogen) and 1x penicillin/streptomycin. The cells were transfected with pcDNA6-TyrRS-V5 (wild type), or pcDNA3.1-ZZ-PARP-1 using Lipofectamine LTX (Invitrogen). Resveratrol (SantaCruz Biotechnologies), at a series of concentrations from 0 to 50 μM were used to treat HeLa cells 0-24 h in experiments described. As the effects of RSV are strongly influenced by the background level of PARP-1 activity, the experiments were done only after checking to verify that background PARP-1 activation was low. Our criterion was to see PARP-1 activation upon serum starvation, along with Hsp72 induction 52 . When serum starvation induces PARP-1 activation with Hsp72 induction within 30-45 min (from the same batch of a split of HeLa cells), we consistently see PARP-1 activation at lower concentrations of RSV (1μM). Cell culture medium was supplemented with Tyr-SA or Gly-SA (RNA-TEC, Coralville, IA) where mentioned. Silencer ® Select Pre-designed siRNA against PARP-1 (siRNA ID#: s1099, 5′-GCAGCUUCAUAACCGAAGAtt-3′), SIRT1 (siRNA ID#: s23770, 5′-GGCUUGAUGGUAAUCAGUAtt-3′) and TyrRS (siRNA ID#: s443, 5′-GGACUUUGCUGCUGAGGUUtt-3′) were purchased from Invitrogen, Carlsbad, CA and was transfected into HeLa cells using Lipofectamine RNAiMAX (Invitrogen). NAMPT, the rate-limiting enzyme in the NAD + salvage pathway, was inhibited using STF-118804 53 according to manufactures' protocol (SelleckChem). The effect of a concomitant increase in nicotinamide production with a reduction of NAD + concentration (leading to SIRT1 inhibition) was monitored by immunoblotting with α-AcK382-p53, an acetylation site known to be specifically targeted by SIRT1 1 . α-pSer15-p53 monitoring indicated if enhanced acetylation preceded the phosphorylation event 54 . Total p53 was blotted with α-p53. Transactivation of p53 was determined by monitoring its known targets, such as p21, PUMA, 14-3-3, FOXO3A, SESN2 and SIRT6. Activation of NRF2 was further confirmed by following HO-1 expression, using the cognate antibodies. Activation of AMPK (Thr172-phosphorylation) mediated through AMP and Ca 2+ influx 25 was monitored using α-pThr172-AMPK. Activation of AMPK on its targets was further determined by both α-pSer36-H2B and by the expression level of NAMPT.
Cell viability assay
HeLa (1×10 6 ) cells were reverse-transfected with siRNAs and viability was monitored using RTCA iCELLigence System (ACEA Biosciences). HeLa cells were cultured in a humidified incubator with 5% CO 2 in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Invitrogen) and 1x penicillin/streptomycin.
Preparation of cell fractions
Protocol for cell fractionation was followed as described previously 12 . Briefly, for whole cell lysate preparation, HeLa cells were dissolved in 1xSDS-PAGE loading buffer containing 300 mM NaCl. For cytoplasmic fraction preparation, HeLa cells were suspended in 0.1 ml of swelling buffer for 6 min on ice, and then incubated with 0.1 ml of plasma membrane lysis buffer for 5 min on ice. The cells were immediately passed through a 21-G needle 10 times and centrifuged for 10 min at 3220g, 4°C. The supernatant was harvested, while the pellets were used for the preparation of nuclear fractions. For this purpose, the pellet (nuclei) was incubated for 30 min at 4°C with 0.2 ml nuclear extraction buffer. Whenever required, PARP-1 (AG14361) and PARG inhibitors (ADP-HPD, Millipore) were added to the cell lysis buffer to ensure unwanted PARylation and removal of PAR chains with PARG.
Immuno-precipitation and Ni-NTA pull-down assays
Protocol for immuno-precipitation was followed as described previously 12 . Briefly, the supernatants were pre-cleared by incubation with protein G beads. The pre-cleared cell lysates were incubated at 4°C for 1 h with either α-PARP-1, α-ATM, α-DNA-PKcs, α-TyrRS, α-Tip60 or non-immune IgG, at a concentration of 5 μg/ml followed by incubation with 30 μl Protein G-beads (pretreated with 10 mg/ml BSA) at 4°C for 1h with rotation. PARP-1 (AG14361) and PARG inhibitors (ADP-HPD, Millipore) were added to the cell lysis buffer to ensure unwanted PARylation and removal of PAR chains with PARG. Immuno-precipitates were washed three times, subjected to SDS-PAGE and immunoblotted with specific antibodies. Whenever mentioned, the ZZ domain allowed immunoprecipitation of ectopically expressed ZZ-PARP-1, using anti-IgG. Whenever Ni-NTA pulldown was performed, proteins with a 6X-His tag were overexpressed in E. coli. Cells were lysed and the supernatant fractions containing the soluble proteins were mixed with HeLa cell lysates. For Ni-NTA pull-downs, normal procedures for immunoprecipitation were followed with 15-20 mM imidazole in the washing buffer.
Animal experiments
All experiments were approved by the Scripps Research Institute, IACUC (protocol number 13-0002) and conducted by the mice facility at The Scripps Research Institute. BALB/cByJ mice were originally purchased from Jackson Laboratories. Six week old male mice were kept with a 12 h light-dark cycle with free access to food and water for 3 days before conducting the experiment. For all studies, mice were dosed once and collected sample after either at 30 min or at 24 h. Briefly, activation of PARP-1 in mouse tissues treated with resveratrol was performed by the intravenous (IV) injection of a 100 μl sample of resveratrol (10 μM) in PBS into 8 mouse tails (0.012 mg/kg). A 100 μl PBS injection was used as a control in 6 mice. Tissue samples were collected from 4 resveratrol treated mice and 3 control mice after 30 min treatment. Tissue samples from the remaining mice were collected after 24h. In a different experiment, blocking of resveratrol mediated activation of PARP-1 by Tyr-SA was analyzed with 5 groups of two mice each, a 100 μl sample of resveratrol (10 μM ) in PBS alone and, separately, with Tyr-SA (5 μM), Gly-SA (5 μM), cycloheximide (5 μM) or the AG14361 PARP-1 inhibitor (10 μM) was IV-injected. A 100 μl PBS injection with Tyr-SA was used in a control group (2 mice) as indicated. Tissue samples were collected after 30 min treatment. Muscle or heart tissues samples were homogenized and analyzed by immunoblotting for the status of poly-ADP-ribosylation and associated signaling events.
Recombinant protein purification
Human TyrRS and PARP-1 and their variants were purified as previously described 10, 12 .
Briefly, DNA encoding either full-length TyrRS (aa 1-528), mini-TyrRS (aa 1-341), dNTyrRS (aa 237-528), CT-TyrRS (aa 324-528), was cloned into Nde-I/Hind-III sites of pET-20b vector (Novagen, Gibstown, NJ). The expressed proteins include a 6-His tag from the vector sequence. The full-length PARP-1 and its variants (N-terminal domain (NTD) and C-terminal domain (CTD)) were cloned into pET 20b vector. All proteins having a Cterminal His-tag were expressed in E. coli strain BL21 (DE3) by induction for 4h with 1 mM isopropyl β-D-thiogalactopyranoside. Proteins were purified from the supernatants of lysed cells using Ni-NTA agarose (Qiagen, Chatsworth, CA) column chromatography according to the manufacturer's instruction. We also included an additional high salt 2-column wash (1-1.5 M NaCl), to remove the endogenous DNA/RNA associated with the purified protein.
The NaCl concentration was increased to 1.5M in increments and returned to final elution buffer having 250 mM NaCl in decrements. All the proteins were subjected to a gelfiltration (S-200) chromatography and collected the protein peak corresponding to homogenous protein. As endotoxin associated with purified protein interfered with the inhibitory/activating effect of RSV on TyrRS/PARP-1, the complete protein purification included an additional endotoxin removal step. The purified protein was further passed through a column containing Detoxi-Gel ™ (Pierce-Thermo Scientific, IL, USA) and followed the manufactures instructions. The final endotoxin level (0.5 EU/mg/ml) was measured using The Endosafe R -PTS kit (Charles River Laboratories, Charleston, SC). The quality of each protein purification was validated by SDS-PAGE analysis.
Protein crystallization and data collection
All the steps were followed as mentioned in the previously report for mini-TyrRS crystallization 10 . Briefly, mini-TyrRS was mixed with either 1 mM RSV or 2 mM Tyrosine and incubated at 4°C for 16h. Before setting up the crystallization trials, the protein samples were subjected to high-speed centrifugation (13000 rpm for 15 min) to remove all the precipitants and transferred the clear soluble fraction to a new tube. The crystallization trials were done using 2.1 M (NH 4 ) 2 SO 4 , 0.1 M NaH 2 PO 4 /K 2 HPO 4 (pH 6-8), and 2% acetone at room temperature. Although, mini-TyrRS crystals with L-tyrosine were grown in 3 days (data collected at Stanford Synchrotron Radiation Lightsource), crystals with RSV were grown only after 3-4 months at around pH 7. X-ray data were collected at 2.1A° using the in-house x-ray diffraction facility (The Scripps Research Institute, La Jolla). Data were integrated and scaled using HKL2000. The electron density was refined by molecular replacement (CNS and CCP4/REFMAC suite and Coot) using the known structure of mini-TyrRS (Extended Data Table 1 ) and structures were deposited to PDB (ID code 4Q93 and 4QBT).
ATP-PPi exchange assay
Tyrosyl adenylate synthesis was measured by using the tyrosine-dependent ATPpyrophosphate (PPi) exchange assay. A mixture containing 100 mM Hepes (pH 7.5), 20 mM KCl, 2 mM ATP, 1 mM NaPPi, 2 mM DTT, 250-500 μM L-tyrosine, 10 mM MgCl 2 , and 0.01 mCi/ml Na[ 32 P]PPi was added to 50-100 nM purified TyrRS (endotoxin free, 0.5EU/mg/ml), pre-incubated with 0-1mM RSV at 4°C for 30 min. The ATP-PPi exchange reaction was incubated at room temperature, and aliquots were removed at specified time intervals and quenched in a mixture containing 40 mM NaPPi, 1.4% HClO 4 , 0.4% HCl, and 8% (wt/vol) of activated charcoal. After thoroughly mixing, the charcoal was filtered and washed with a solution of 7% HClO 4 and 200 mM NaPPi using Spin-X Centrifuge Filters (Corning, Corning, NY) containing 0.45-μm pore-size cellulose acetate filters. After drying, the charcoal was punched into scintillation vials and the radioactivity of the ATP bound to the charcoal mixture was measured by scintillation counting.
In vitro PARylation assay
Protocol followed as described previously 12 . Briefly, 5 μl recombinant PARP-1 (2μg ) was mixed with 5 μl recombinant TyrRS (0-50 μM) and depending on the experiment either RSV, TyrSA, DNA or AG14361 were also added (5 μl HeLa cells (1× 10 6 ) were reverse-transfected with siRNA targeted to TyrRS or PARP-1. An siRNA Con (a scrambled sequence of siRNA PARP-1 ) was used as a control. Viability was monitored using the RTCA iCELLigence System (ACEA Biosciences). Samples were treated with RSV (5μM) at 60h and monitoring was continued for another 2h for siRNA TyrRS (total of 62h of monitoring) and for another 16h for siRNA Con and siRNA PARP-1 (total 76h monitoring). HeLa cells were treated with siRNA SIRT1 for 60 h to knockdown SIRT1. HeLa cells were treated with RSV (5 μM) for another 4 h and samples were collected intervals as indicated. Samples were analyzed for down stream signaling markers using appropriate antibodies. control. f, RSV treatment enhances TyrRS interaction with and activation of PARP-1 in the muscle tissue. g and h, Resveratrol-mediated activation of PARP-1 (g, monitored by PARylation status and h, monitored by acetylation status) is blocked by Tyr-SA in the mouse heart tissues.
Extended Data Table 1 Data collection and refinement statistics. Numerical parameters for the RSV-TyrRS and L-Tyr-TyrRS co-crystals are listed and compared side-by-side in separate columns.
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